menu search

SBTX / Silverback Therapeutics Axes Lead Immuno-Oncology Candidates, Lays Off 27% Workforce

Silverback Therapeutics Axes Lead Immuno-Oncology Candidates, Lays Off 27% Workforce
Silverback Therapeutics Inc (NASDAQ: SBTX) undertakes “strategic realignment,” revealing it would drop its two lead cancer programs and lays off more than a quarter of its staff. Silverback will continue the advancement of early-stage discovery research. Read More
Posted: Apr 1 2022, 11:20
Author Name: Benzinga
Views: 103112

SBTX News  

Silverback Therapeutics Axes Lead Immuno-Oncology Candidates, Lays Off 27% Workforce

By Benzinga
April 1, 2022

Silverback Therapeutics Axes Lead Immuno-Oncology Candidates, Lays Off 27% Workforce

Silverback Therapeutics Inc (NASDAQ: SBTX) undertakes “strategic realignment,” revealing it would drop its two lead cancer programs and lays of more_horizontal

Silverback Therapeutics shuts down oncology program, plans to lay off 27% of workforce

By GeekWire
March 31, 2022

Silverback Therapeutics shuts down oncology program, plans to lay off 27% of workforce

Silverback Therapeutics will lay off 27% of its workforce and close its oncology program, the Seattle company announced Thursday in its fourth quarter more_horizontal

Goldman Sachs Has 5 Buy-Rated Stocks Under $10 With 100% to 600% Upside Potential

By 24/7 Wall Street
February 19, 2022

Goldman Sachs Has 5 Buy-Rated Stocks Under $10 With 100% to 600% Upside Potential

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in th more_horizontal

Goldman Sachs Has 5 Buy-Rated Stocks Under $10 With 100% to 600% Upside Potential

By 24/7 Wall Street
February 19, 2022

Goldman Sachs Has 5 Buy-Rated Stocks Under $10 With 100% to 600% Upside Potential

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in th more_horizontal

Goldman Sachs Has 5 Buy-Rated Stocks Under $10 With 100% to 600% Upside Potential

By 24/7 Wall Street
February 19, 2022

Goldman Sachs Has 5 Buy-Rated Stocks Under $10 With 100% to 600% Upside Potential

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in th more_horizontal


Search within

Pages Search Results: